-
Mashup Score: 9Cancer Screening | Resources and FAQ - 1 year(s) ago
Regular cancer screening tests can help find & treat cancers early, when it might be easier to treat. See our resources for recommended screening tests for ages 25 and up.
Source: www.cancer.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 0EHA Library - The official digital education library of European Hematology Association (EHA) - 1 year(s) ago
Access educational materials, eLearning activities, accredited Live webinar sessions with polls and chat on this fast Digital Library and Hybrid Virtual Event Platform powered by MULTILEARNING LMS.
Source: library.ehaweb.orgCategories: General Medicine News, PayerTweet-
¡Hola Madrid! 🇪🇸 We’re thrilled to be here for @EHA_Hematology’s Annual Congress. Join us at Booth H2 to learn more about @Amgen’s #EHA2024 updates for patients with blood cancer: https://t.co/sBhE3uProv https://t.co/idbUsCEk54
-
-
Mashup Score: 12mcrc - 1 year(s) ago
Discover how KRAS G12C mutation may be associated with a worse prognosis in patients with mCRC.
Source: www.findkrasg12c.comCategories: General Medicine News, PayerTweet-
👋 #ASCO24 attendees! We’re investigating a new way to attack metastatic colorectal cancer (mCRC) – one that targets the KRAS G12C oncogene. Discover the facts about this driver mutation: https://t.co/DcsX0CMCEc https://t.co/CypFJzfHNC
-
-
Mashup Score: 5Program Guide – ASCO Meeting Program Guide - 1 year(s) ago
Presenter: Jens Hoeppner, FAChirg, FACS, MD Presenter: Christian U. Blank, MD, PhD Presenter: Suresh S. Ramalingam MD, FASCO, FACP Presenter: David R. Spigel, FASCO, MD INAVO120 (NCT04191499) showed significantly and meaningfully improved investigator-assessed progression-free survival (PFS; stratified hazard ratio 0.43) with Inavo+Palbo+Fulv v Pbo+Palbo+Fulv, and manageable safety and tolerability. To further characterize the substantial benefit/risk of the Inavo triplet, we assessed additional clinically
Source: meetings.asco.orgCategories: General Medicine News, PayerTweet-
🚨Oncology’s biggest conference kicks off today in Chicago! If you’re attending @ASCO’s Annual Meeting, join us at booth #30073 to explore @Amgen’s robust oncology portfolio and pipeline. 🔗Learn about our presentations: https://t.co/VPw4uEnQUZ #ASCO24 https://t.co/O43yydQfuL
-
-
Mashup Score: 4Expanding Innovation in BiTE® Technology for Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - 1 year(s) ago
After decades of minimal advancements in the SCLC treatment landscape, there is now a new treatment option available for patients living with this advanced disease.
Source: www.amgen.comCategories: General Medicine News, PayerTweet-
Rayanne and Dennis’s experience navigating extensive-stage small cell lung cancer demonstrates why new treatment options are urgently needed. At @Amgen, we’re committed to offering hope to those facing this devastating cancer: https://t.co/dhoTzrIYVJ https://t.co/88JZEXhpYA
-
-
Mashup Score: 37Expanding Innovation in BiTE® Technology for Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - 1 year(s) ago
After decades of minimal advancements in the SCLC treatment landscape, there is now a new treatment option available for patients living with this advanced disease.
Source: www.amgen.comCategories: General Medicine News, PayerTweet-
Rayanne and Dennis’s experience navigating extensive-stage small cell lung cancer demonstrates why new treatment options are urgently needed. At @Amgen, we’re committed to offering hope to those facing this devastating cancer: https://t.co/phNk6N7BXl https://t.co/EPpQiZsSIx
-
-
Mashup Score: 4Expanding Innovation in BiTE® Technology for Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - 1 year(s) ago
After decades of minimal advancements in the SCLC treatment landscape, there is now a new treatment option available for patients living with this advanced disease.
Source: www.amgen.comCategories: General Medicine News, PayerTweet-
Oncologists may soon have a new weapon in their arsenal to attack small cell lung cancer. @Amgen developed a potential targeted therapy that empowers a patient’s own immune system to seek out and help fight cancer cells. 🔗Learn more: https://t.co/BBzK6gQ7rR https://t.co/iTJT3d3MQO
-
-
Mashup Score: 5HOPE Summit | LUNGevity Foundation - 1 year(s) ago
LUNGevity’s HOPE Summit is a unique weekend conference for patients with lung cancer, survivors, and caregivers.
Source: www.lungevity.orgCategories: General Medicine News, PayerTweet-
Over the weekend patients, survivors and caregivers from across the country convened in Atlanta for @LUNGevity’s annual #HOPESummit, a unique event dedicated to living well with lung cancer. @Amgen was honored to be part of #ThisIsHope24. 🔗Learn more: https://t.co/prUwT1mxR1 https://t.co/ZtnBSBAp0X
-
-
Mashup Score: 2Amgen Pipeline - 1 year(s) ago
A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used whenever possible to strengthen the evidence base for as many of our programs as possible.
Source: www.amgenpipeline.comCategories: General Medicine News, PayerTweet-
🔬Oncology #research has the power to change lives. From biomarker-based targeted therapies to novel combination approaches, @Amgen pioneers meaningful research in tough-to-treat cancers with high unmet needs. 🔗 Explore our diverse pipeline: https://t.co/jkSqJN9CvL #NCRM24 https://t.co/6Nnoi7KRFR
-
-
Mashup Score: 4Navigating the Landscape of Precision Medicine in Gastric Cancer: FGFR2b Protein Overexpression as an Emerging Biomarker - 1 year(s) ago
Gastric and gastroesophageal junction (G/GEJ) cancers, otherwise known as stomach cancer, is the fourth leading cause of cancer-related death worldwide, with the highest incidence rates occurring in Eastern Asia and Eastern Europe. Exploring the role of FGFR2b protein overexpression in gastric cancer represents an exciting potential for targeted therapy.
Source: www.amgen.comCategories: General Medicine News, PayerTweet-
How can we personalize gastric cancer care? At @Amgen, we’re exploring the full potential of #FGFR2b as a target 🎯 for new therapies. 🔗Learn more about FGFR2b: https://t.co/MBdteNkhIK https://t.co/7w7ZDe6rbm
-
If you have a prostate, you need to know about screening. Regular screenings help detect prostate cancer early – when it’s often easier to treat. Visit https://t.co/rfed7vUmeI to learn more. #MensHealthMonth https://t.co/PkkDEnIOgT